Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Completed
80 enrolled
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Active not recruiting
2,907 enrolled
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
Completed
86 enrolled
HER2 CR
Active not recruiting
50 enrolled
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
Active not recruiting
13 enrolled
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
Terminated
538 enrolled 9 charts
AryoTrust® (Trastuzumab) Safety Study
Completed
597 enrolled
BiOnHER
Unknown
80 enrolled
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
Completed
1,209 enrolled
A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer
Unknown
50 enrolled
Neoadjuvant Treatment of Breast Cancer
Not yet recruiting
300 enrolled
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
Unknown
40 enrolled
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
Unknown
240 enrolled
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
Unknown
30 enrolled
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Unknown
80 enrolled
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
Unknown
200 enrolled
HerSCin
Completed
1,006 enrolled
MotHER
Completed
20 enrolled
Breast Cancer Treatment Based on Organ-like Culture
Unknown
300 enrolled
PACE in BC
Completed
133 enrolled
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
Completed
3,942 enrolled
Prognostic and Predictive Factors for Small Breast Tumors
Completed
35,002 enrolled
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
Completed
81 enrolled
HERODOT
Terminated
250 enrolled 12 charts
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
Completed
160 enrolled 13 charts
microRNA of Human Epidermal Growth Factor Receptor 2 (HER2)Positive Patient Treated With Herceptin
Unknown
300 enrolled
Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients
Suspended
50 enrolled
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
Completed
36 enrolled 15 charts
CADY Study ICORG 08-01
Completed
480 enrolled
Brain Metastasis in Breast Cancer Patients
Completed
1 enrolled